Comparison of the Neuroprotective Effects of Adrenoceptor Drugs in Retinal Cell Culture and Intact Retina

Darryl C. Baptiste,1,2 Andrew T. E. Hartwick,1,3 Christine A. B. Jollimore,1,2 William H. Baldridge,1,3,4 Balwantray C. Chauban,1,4,5 François Tremblay,1,4,5 and Melanie E. M. Kelly1,2,4

PURPOSE. The efficacy of β2-adrenoceptor (AR)-selective (betaxolol and metoprolol) and nonselective (timolol) antagonists and the α2-AR agonist UK14,304 as retinal neuroprotectants was compared and contrasted in an in vitro glutamate excitotoxicity model. The ability of UK14,304, brimonidine, and betaxolol to alter glutamate-receptor–induced changes in intracellular calcium ([Ca2+]i) was also determined in isolated retinal neurons and retinal ganglion cells (RGCs) in an intact retina preparation.

METHODS. Neuronal survival was measured in mixed retinal cell cultures treated for 24 hours with media containing 100 μM glutamate, with or without the addition of each of the drugs (1–1000 μM). Effects of glutamate on [Ca2+]i were also investigated in a C6 glioma cell line. Glutamate-induced changes in [Ca2+]i, with and without UK14,304, and its analogue brimonidine were assessed by calcium-imaging techniques in retinal neurons in culture. The effect of betaxolol on [Ca2+]i was investigated in RGCs in intact rabbit retina.

RESULTS. In cell cultures, 10–1000 μM glutamate resulted in a dose-dependent loss of neurons, but not of glia. The absence of glutamate toxicity in glia was confirmed in C6 glioma cells. Betaxolol, but not timolol or metoprolol, significantly increased survival (from 52% of control in glutamate-only to 78% with 10 μM betaxolol) after excitotoxic insult. UK14,304 also increased survival (from 62% of control in glutamate only to 100% and 101% of control with 10 and 100 μM UK14,304, respectively). This effect was blocked by the specific α2-antagonist, yohimbine. Both UK14,304 and brimonidine (10–100 μM) reduced glutamate-induced [Ca2+]i increases in retinal neurons in culture. The actions of the α2-agonists in reducing glutamate-induced [Ca2+]i increases, were reduced by yohimbine (1 μM). Betaxolol (100 μM) reduced N-methyl-D-aspartate (NMDA)-induced increases of [Ca2+]i in RGCs in intact retina.

CONCLUSIONS. Betaxolol reduced glutamate excitotoxicity in retinal neurons in vitro through a mechanism independent of β-AR interactions. UK14,304, acting through α2-ARs, was also neuroprotective in vitro. The neuroprotective actions of betaxolol and the α2-agonists on retinal neurons may be due, at least in part, to a direct reduction of glutamate receptor-mediated increases of [Ca2+]i. (Invest Ophthalmol Vis Sci. 2002;43:2666–2676)

Retinal ganglion cell (RGC) loss is a feature of a number of diseases that decrease visual function, including primary open-angle glaucoma and anterior ischemic optic neuropathy. Although accumulated evidence suggests that RGCs die by apoptosis in open-angle glaucoma and in experimental animal models of optic nerve damage, the exact sequence of damage leading to neuronal loss has not been resolved. Intraocular pressure and a variety of additional factors are probably involved. Interruption of trophic support; oxidative stress; intracellular ion and electrolyte disturbance; increased extracellular glutamate levels, together with excessive stimulation of excitatory amino acid receptors (excitotoxicity); and pathologic increases in intracellular calcium ([Ca2+]i) ion concentration have all been implicated in RGC loss. 

The presence of apoptosis as a feature of glaucoma indicates that the pathways of cell death that contribute to glaucomatous damage may be similar to those observed in other neurodegenerative diseases of the central nervous system. Thus, intervention at various upstream points in the apoptotic cascade, such as glutamate receptors, Ca2+ influx, and activation of proapoptotic genes may provide therapeutic targets for drugs that could delay or ameliorate RGC loss in glaucoma and optic nerve neuropathies. In support of this, glutamate receptor antagonists, Ca2+-channel blockers, and caspase protease inhibitors have all been reported to decrease neuronal apoptosis in animal and cell culture models of retinal neuron death.

Adrenoceptor (AR) agonists and antagonists are frequently used in the medical management of glaucoma and decrease IOP by acting at sites in the ciliary processes and various outflow pathways to decrease aqueous humor production and increase outflow, respectively. An additional neuroprotective action of these agents, either alone or in combination with other drugs would therefore be of considerable benefit in the chronic treatment of glaucoma. Both the β1-AR blocker, betaxolol, and the α2-AR agonist, brimonidine, in addition to their ocular hypotensive actions, have been cited as neuroprotectants in various animal models of retinal and optic nerve injury. However, because these in vivo studies used systemic or topical drug application, it is not possible to unequivocally rule out the actions of these compounds at target sites remote from retinal neurons (i.e., anterior segment and vascular beds). Therefore, it remains unclear whether the neuroprotection afforded by these drugs is due, at least in part, to a direct action on retinal neurons and, if direct, what mechanisms mediate such neuroprotection.

In this study we compared and contrasted the neuroprotective effects of a variety of β-AR blockers (betaxolol, metoprolol, and timolol) and α2-AR-agonists (UK14,304 and brimonidine). The objectives of the study were to ascertain whether any of
Neuroprotective Effects of Adrenoceptor Drugs In Vitro 2667

these agents protect retinal neurons from glutamate excitotoxicity in vitro by increasing neuronal survival, and if so, to determine whether such neuroprotection effects are associated with receptor-mediated mechanisms and/or decreased calcium-influx, as assessed with calcium-imaging in both isolated retinal neurons and in RGCs in an intact retina preparation.

MATERIALS AND METHODS

Materials

All culture reagents were obtained from Gibco BRL (Burlington, Ontario, Canada), unless noted otherwise. All other drugs and chemicals were obtained from Sigma Chemical Co. (St. Louis, MO), unless noted otherwise. BDNF and CNTF were provided by Regeneron Pharmaceuticals (Tarrytown, NY), betaxolol by Schwarz Pharma (Boulogne-Billancourt, France), and bombinidine tartrate by Allergan (Irvine, CA). Lysing solution (Zapoglobin) was purchased from Coulter Electronics (Hialeah, FL). The Ca$^{2+}$ indicator dyes fura-2 AM, calcium green-1 dextran, and pluronic acid F-127, were purchased from Molecular Probes (Eugene, OR). In all cases l-glutamate was used but is referred to simply as glutamate.

Retinal Cell Cultures

Retinal neurons and glia were isolated from retinas obtained from 6- to 10-day-old Long-Evans rats. All procedures were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the Dalhousie University Committee for the use of Laboratory Animals. Briefly, rat pups were anesthetized with halothane and decapitated. The eyes were enucleated and posterior eyecups were placed in Hank's balanced salt solution (HBSS) and 1% gentamicin. The neural retinas were gently peeled off with fine forceps and incubated at 37°C in 0.02% trypsin for 5 minutes or for 30 minutes in papain (20 U/mL; Worthington Biochemical, Lakewood, NJ). Fetal bovine serum (10%, FBS) was added to the tube to halt the enzyme reaction. Retinal cells were obtained by trituration in growth medium (Neurobasal medium, 10% FBS, 1 ng/mL ciliary neurotrophic factor [CNTF], 10 ng/mL brain-derived neurotrophic factor [BDNF], N${}_2$ supplement, and 1% gentamicin). The resultant cell suspension was seeded at a density of 250,000 cells/mL on poly-l-lysine–coated coverslips in 24-well culture plates. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO$_2$-95% air, and half the growth medium was replaced every 2 to 3 days.

The identification of neurons in the mixed neuron-glia cultures was first established by double-label immunocytochemistry with a mouse antibody against neuron-specific β-tubulin (TUJ1; BabCo, Richmond, CA) and contrasted to the number of glial cells identified with a rabbit antibody against glial fibrillary acidic protein (GFAP). Primary antibody labeling was visualized with fluorescent dye conjugated to secondary antibodies (a goat anti-mouse IgG secondary antibody conjugated to Alexa 546 and goat anti-rabbit IgG secondary conjugated to Alexa 488; both from Molecular Probes). Cell density was determined by direct counts of the number of cells in 10 successive 680 × 460-μm fields (camera field of view for 40× objective) in three separate experiments. A C6 glioma cell line (American Type Culture Collection, Manassas, VA) was used for studies requiring a pure CNS glial culture. These cells were maintained in DMEM containing 10% fetal calf serum.

Cell Survival Assays

Mixed retinal neurons and glial cultures grown for 7 days in 24-well culture dishes were divided into groups and treated for 24 hours with one of the following: (1) treatment medium (TM) consisting of DMEM, 10% FBS, N$_2$ supplement, 10 ng/mL BDNF, 1 ng/mL CNTF, and gentamicin; (2) TM + glutamate (TMG); or (3) TMG + drug (TMG+D). Cell survival was assayed by a cell lysis method, as previously described. Briefly, the cells were removed from the 24-well plates with trypsin and centrifuged for 5 minutes, and the cell pellet was washed and resuspended in 300 μL of a 1:10 dilution of lysing solution. Viable cell nuclei were counted with a hemocytometer. Mean cell counts were obtained from three to four wells per treatment group (TM, TMG, or TMG+D) and expressed as a percentage of the number of viable cells in the control TM group. Mean percentage data ± SEM were obtained from three to six separate experiments. The drugs used were betaxolol, metoprolol, and timolol (β-blockers) and UK14,304 and brimonidine (α$_2$-agonists), and the effect of each was tested over the range of concentrations from 1 to 1000 μM. The specificity of the effect of UK14,304 was further investigated with the α$_2$AR antagonist yohimbine at 1 and 10 μM. Solutions of UK14,304 were prepared from stocks dissolved in dimethyl sulfoxide (DMSO). Therefore, in experiments in which UK14,304 was used, equivalent amounts of DMSO were also added to the other treatment solutions (TM, TMG).

Differences between mean data were compared for statistical significance with a two-tailed t-test or one-way analysis of variance (ANOVA) and the Dunnett multiple comparison test (Instar; GraphPad, San Diego, CA).

Calcium Imaging of Retinal Neuron Responses to Glutamate

Isolated rat retinal neurons were maintained in serum-free Neurobasal medium with 1 mM glutamine, 10 μg/mL gentamicin, 2% B27 supplement, 40 ng/mL BDNF, and 10 μM forskolin. The neurons were loaded with the ratiometric calcium-indicator dye fura-2. Cells were incubated in 5 μM fura-2-acetoxyethyl ester (AM) dissolved in modified HBSS (described later) for 20 minutes in the dark at 37°C. The fura-2 AM was first dissolved in DMSO (0.1% final concentration in HBSS) and then solubilized in HBSS containing 0.1% pluronic acid F-127. After loading, the cells were washed in HBSS for at least 15 minutes before imaging.

To assess the effect of glutamate on [Ca$^{2+}$], we used a modified Mg$^{2+}$-free HBSS (pH 7.4, 20 mM HEPES, 1.5 mM CaCl$_2$). All treatment solutions containing glutamate, UK14,304, and yohimbine were prepared from stocks and dissolved in the modified HBSS. The fura-2–loaded neurons plated on coverslips were maintained in a chamber (ΔTCT; Bioptechs, Butler, PA) that was constantly superfused with HBSS at 34°C to 36°C (30-27° inline heater, TC-324B controller; Warner Instruments, Hamden, CT) and bubbled with 100% oxygen. Solutions were delivered to the chamber by a peristaltic pump (Gilson, Middleton, WI) at a rate of 2 mL/min. During treatments, image pairs were collected as often as every 3 seconds, but to limit photodamage, images were collected less frequently (20 seconds) during intervening periods.

The neurons loaded with fura-2 were imaged with a cooled charge-coupled device (CCD) camera (Sensicam; PCO Computer Optic, Kelheim, Germany) fitted to a microscope (Axioskop FS; Carl Zeiss, Oberkochen, Germany) using a water-immersion objective (numeric aperture 0.80; Achroplan 40×; Zeiss). Fura-2 fluorescence was produced by excitation from a 75W xenon lamp (Ludl Electronic Products, Hawthorne, NY) and appropriate filters (XP04 set, excitation 340 or 380 nm; emission 510 nm; dichroic >430 nm; Omega Optical, Brattleboro, VT). To reduce photodamage and photobleaching, excitation illumination was filtered with a –0.5 log neutral density filter and 640 × 512-pixel or 320 × 256-pixel images acquired. The duration of illumination was limited (400 msec) by an electronic shutter (Uniblitz, Rochester NY). Images at 340 and 380 nm excitation were captured and converted to ratiometric (340/380 nm) images by an imaging system (Imaging Workbench 2.2, Axiom Instruments, Foster City, CA) and saved to the hard disk of a computer. The mean ratio over a large area of a neuron, well separated from the edge of the cell, was measured for each captured ratiometric image.

Free [Ca$^{2+}$], was elevated in cultured cells by application of a short pulse (20 seconds) of 10 μM glutamate in HBSS. This protocol was chosen because it resulted in reproducible increases of [Ca$^{2+}$], well within the dynamic range (below saturation) of fura-2 fluorescence. The retinal neurons were treated with UK14,304 (10 - 100 μM) or brimonidine (100 μM) for 5 minutes before and 3 minutes after the glutamate burst. Solutions of UK14,304 were prepared from stocks...
dissolved in DMSO. Therefore, in experiments in which UK14,304 was used, equivalent amounts of DMSO were also added to the other treatment solutions. For experiments with yohimbine, the neurons were pretreated first for 5 to 10 minutes with 1 μM yohimbine alone and then with yohimbine and UK14,304 together for the same period as in the experiments with UK14,304 alone. The time between consecutive bursts of glutamate was kept at 10 minutes to allow sufficient time for [Ca\(^{2+}\)]
levels to recover to a baseline level.

The peak fura-2 ratios were normalized to the initial treatment with glutamate and differences between the peak fura-2 ratios (pretreatment, in presence of UK14,304 or brimonidine, and recovery) were tested for statistical significance with the Mann-Whitney rank sum test. All analyses were performed on computer (SigmaStat software; SPSS Science, Chicago, IL).

**RESULTS**

**Immunocytochemical Identification of Neurons and Glia In Vitro**

The identification of neurons in the mixed neuron-glia cultures was first established by using double-label immunocytochemistry with antibodies against neuron-specific β-tubulin and GFAP (Fig. 1). The neuron-specific, β-tubulin–labeled cells (neurons) had compact cell bodies and processes longer than twice the size of the somata, whereas GFAP labeling was restricted to cells (glia) with flattened morphology and processes less than twice the size of the somata. Colocalization was never observed. Therefore, in subsequent survival and calcium-imaging studies, cells were classified as neurons if they possessed the appropriate morphology together with processes (neurites) greater than twice the size of the somata. Cells without these long processes were considered to be glia. On average, neurons constituted approximately 35% to 40% of the total population of cultured cells.

**Effect of Glutamate on Retinal Neuron Survival**

The effects of increasing concentrations of glutamate on neuronal survival were examined in mixed rat retinal neuron-glial cultures. Addition of glutamate at concentrations of 1 to 1000 μM to mixed retinal cell cultures for 24 hours resulted in a significant dose-dependent decrease in the number of viable cells from 57% ± 2% of the control group at a dose of 1 μM glutamate, to 51% ± 1%, 37% ± 1%, and 19% ± 0.5% of the control group at 10, 100, and 1000 μM glutamate, respectively (Fig. 2A). In subsequent experiments, a dose of 100 μM glutamate was used in cell survival assays, because this was the dose in mixed retinal cell cultures that consistently produced approximately 50% or greater cell loss. The cell loss in mixed cultures exposed to glutamate consisted primarily of neurons (Fig. 2B). After 24 hours' exposure to glutamate, there was a 91% decrease (P < 0.01) in the number of neurons, defined by the presence of neurites, but only a 14% decrease (P > 0.50) in the number of glial cells, defined by absence of neurites, flattened morphology, and positive staining for GFAP (Fig. 2B). Figure 2C shows the response of a pure glial cell line (C6 glioma) to glutamate treatment. These data demonstrate that 10 and 100 μM glutamate had no significant (P > 0.40) effect on glial cell survival.

**Effects of Betaxolol, Timolol, and Metoprolol on Retinal Neuron Survival**

Figure 3 shows data from experiments examining the survival of retinal cultures in the presence of 100 μM glutamate alone.
or glutamate plus various concentrations (1-1000 μM) of the β₁-selective AR blockers betaxolol and metoprolol or the non-selective β-AR blocker timolol. Betaxolol produced a dose-dependent increase in viable cells up to 100 μM, compared with the glutamate-only treatment group (Fig. 3A). Viable cells (mean ± SEM) in the presence of 1, 10, 100, and 1000 μM betaxolol were 56% ± 10%, 78% ± 2%, 93% ± 14%, and 86% ± 30% of control glutamate-free group compared with 53% ± 4% of control in the presence of glutamate alone. This increase in cell survival was significant at 10 μM betaxolol (P < 0.01) with increased variability at higher doses limiting the significance (P > 0.05 and P > 0.30 at 100 and 1000 μM, respectively) of the effect of betaxolol. In contrast to betaxolol, the nonspecific β-AR blocker timolol failed (P > 0.50) to increase cell survival at all doses tested (1-1000 μM) over that observed in the glutamate-only treatment group (Fig. 3B). We also tested another β₁-selective AR blocker, metoprolol, at 1 to 1000 μM (Fig. 3C). As with timolol, the number of cells surviving in the metoprolol-treated groups was not significantly different (P > 0.50) from that in the glutamate-only group at all doses tested.

**Effect of UK14,304 on Retinal Neuron Survival**

In the groups treated with a dose of 10 or 100 μM UK14,304 plus glutamate (Fig. 4A) there was a significant increase (P < 0.05) in cell survival (109% ± 15% and 102% ± 12% of control, respectively) compared with that in the glutamate-only treatment groups (62% ± 3%). In the presence of 10 μM UK14,304 and 1 and 10 μM yohimbine (Fig. 4B), the number of surviving cells was not significantly different from that in the glutamate-only treatment group, but was significantly different from the glutamate plus α₂-AR agonist-treated group (P < 0.05). This suggests that in contrast to the β-AR blocker betaxolol, the α₂-AR agonist UK14,304 exerts a neuroprotective effect on retinal neurons through interacting with α₂-AR on retinal neurons and/or glia.

**Effect of α₂-AR Activation on the Glutamate-Stimulated [Ca \(^{2+}\)] Increase in Isolated Rat Retinal Neurons**

Glutamate (10 μM) increased the fura-2 fluorescence ratio from a resting level of approximately 0.5 (Fig. 5A) to a peak of approximately 1.1 during exposure to 10 μM glutamate (Fig. 5B). One hundred twelve cells were studied and, on average, 10 μM glutamate produced a peak ratio of 1.07 ± 0.01 (mean ± SEM), increasing from an average resting ratio of 0.51 ± 0.01.

In the presence of 10 or 100 μM UK14,304, there was a significant decrease in the peak ratio reached by exposure to 10 μM glutamate. For example, in the cell shown in Figure 6A the presence of 100 μM UK14,304 reduced the glutamate-induced peak fura-2 ratio to 0.997, an 11% decrease from the control response of 1.12. On average, UK14,304 reduced sig-

...
ni
cifi

s

sig
nificantly (P < 0.01) the effect of 10 μM glutamate on the
peak fura-2 ratio with a dose-dependent decrease of 7% ± 1%
(n = 21) and 15% ± 1% (n = 31) for 10 and 100 μM
UK14,304, respectively (Fig. 6D). In the example shown in
Figure 6A, there was essentially complete recovery of the

FIGURE 3. Neuroprotective effects of the βAR blockers on cultured retinal
neurons. Retinal cell cultures were plated at a density of 250,000 cells/mL
and divided into treatment groups consisting of TM only, TMG (100 μM), or
TMG (100 μM) + various doses (1-1000 μM) of the β-AR blockers (A) betaxolol,
(B) timolol, and (C) metoprolol and incubated for 24 hours. Cell survival
was then assessed by determining the number of intact nuclei after cell lysis.
Data are the mean ± SEM of results of three separate experiments, and
expressed as a percentage of the TM control group (100%). *P < 0.05.

FIGURE 4. Neuroprotective effects of the α2-AR agonist, UK14,304 on
cultured retinal neurons. Retinal cell cultures were plated at a density
of 250,000 cells/mL and then divided into experimental groups con-
sisting of (A) TM, TMG (100 μM), or TMG (100 μM) + various doses
(1-1000 μM) of UK14,304 and (B) TM, TMG (100 μM), or TMG (100
μM) + 10 μM UK14,304 or 10 μM UK14,304 in combination with 1 or
10 μM yohimbine. All experimental groups were incubated for a
further 24 hours before cell survival was assessed from the number of
intact nuclei after cell lysis. Data are the mean ± SEM of results in three
separate experiments, and expressed as viable cells in each experimen-
tal group as a percentage of the TM control group (100%). *P < 0.05.
response to 10 μM glutamate after washout of UK14,304. On average, however, recovery was incomplete (Fig. 6D). Although the response to glutamate after washout of UK14,304 remained significantly different from the response produced before treatment with UK14,304 ($P < 0.01$) the peak ratio was significantly increased compared with that achieved during the treatment ($P < 0.01$). Similar results were achieved when brimonidine, an aqueous-soluble analogue of UK14,304,
was used (Fig. 7). The glutamate response was reduced by 17% ± 3% (n = 5) in the presence of 100 μM brimonidine and showed some recovery (10% ± 4% less than control response) after washout. The lack of full recovery was not due to a reduction of the response to glutamate, because multiple treatments with glutamate in the absence of UK14,304 or brimonidine produced similar ratio increases (data not shown, but see Fig. 6B). In some cells, such as the cell illustrated in Figure 7A, UK14,304 or brimonidine decreased the resting fura-2 ratio, but on average the decrease was not statistically significant.

To determine whether the effect of UK14,304 on glutamate-induced elevations of [Ca^{2+}] was due to the specific action at α_2-ARs, the specific antagonist yohimbine was used. Initial experiments showed that 1 μM yohimbine alone had no effect (n = 20; P > 0.05) on the glutamate-induced increase of [Ca^{2+}]_i.
[Ca$^{2+}$]], (Fig. 6B, 6D). These experiments also demonstrated that the reduced peak ratio during and after UK14,304 treatment was not simply due to a reduction of the response of the cells to glutamate over time or a result of repeated glutamate treatments. Yohimbine (1 μM) limited the effect of UK14,304 on glutamate-induced increases of [Ca$^{2+}$]. This is illustrated graphically for a single cell in Figure 6C, where the effect of 100 μM UK14,304 was essentially abolished by yohimbine. On average (Fig. 6D), 1 μM yohimbine reduced but did not completely eliminate the effect of UK14,304. Although glutamate responses in the presence of both yohimbine and UK14,304 did not reach control (pretreatment) levels (P < 0.05), the peak ratio obtained was greater than in the presence of UK14,304 alone and this was statistically significant (n = 20, Kruskal-Wallis; P < 0.01; Fig. 6D).

**Effect of Betaxolol on NMDA-Induced Increases of Rabbit RGCs [Ca$^{2+}$] in Intact Retina**

RGCs within the ganglion cell layer of the rabbit retina were loaded with CaGD (Fig. 5C) and treated with 50 μM NMDA (Fig. 5D). NMDA was used instead of glutamate, because the uptake of glutamate by neurons and glia in intact retina preparation severely limits the level of extracellular glutamate, even if applied exogenously.43 Although there was also some loading of axons with CaGD (Fig. 5C), NMDA treatment did not increase fluorescence within axons. Treatment with 100 μM betaxolol reduced the increase of CaGD fluorescence in RGCs produced by 50 μM NMDA (Fig. 8). The protocol used tested the response to 50 μM NMDA first in the presence of 100 μM betaxolol and then after approximately 10 minutes’ washout. As described previously,40 this protocol limits reduction of responses that can occur with multiple increases of [Ca$^{2+}$] in this preparation. An optical recording from a single RGC within the rabbit ganglion cell layer is shown graphically in Figure 8A. The tissue was treated with 100 μM betaxolol for 10 minutes, but at 7 minutes was also exposed to a 2-minute pulse of 50 μM NMDA. In the cell illustrated (Fig. 8A) this resulted in an increase of CaGD fluorescence (ΔF/F) of less than 0.2. After approximately 10 minutes’ washout the tissue was treated again with 50 μM NMDA, and the response was much larger, exceeding a ΔF/F of 0.6. Average results from 11 RGCs are shown in Figure 8B. The responses have been normalized to the control (50 μM NMDA alone) treatment and show that, in the presence of 100 μM betaxolol, there was an approximate 40% decrease (P < 0.05) of the response of the cell to 50 μM NMDA.

**DISCUSSION**

There is now increasing evidence that both the β1-AR antagonist betaxolol and α2-AR agonists, such as brimonidine, decrease RGC cell death subsequent to increased intraocular pressure, retinal ischemia, or optic nerve crush.57–58 However, all these studies were performed in vivo, and drugs were applied topically or systemically, making it impossible to determine whether the action of the drugs was directly neuroprotective or indirect, affecting local blood supply, inflammatory mediators or other nonretinal ocular tissues. Although no studies have assessed the effect of AR drugs on retinal neuron survival in vitro, a few studies have examined the effects of such drugs on ion channels but, for the most part, in neurons isolated from lower vertebrate retinas.54,43,44

Our experiments used a mammalian (rat) in vitro cell culture model of retinal excitotoxicity to examine the neuroprotective actions of the βAR blockers, betaxolol, metoprolol, and timolol and the α2-AR agonist UK14,304. This in vitro model allowed the actions of the drugs to be studied directly on retinal neurons and glia in isolation of vascular actions and systemic effects. In our mixed retinal cultures, exposure to exogenous glutamate (10–100 μM) produced an approximate 40% to 50% reduction in the number of cells during a 24-hour period. Immunocytochemical and morphologic identification determined that most of the cell death was neuronal. Glial cells in mixed cultures were relatively resistant to such doses of glutamate, and cells from a purified glial cell line (C6 glioma) were also resistant to glutamate over the same range of concentrations (10–100 μM).

Of the β-blockers tested, only betaxolol increased cell survival after excitotoxic insult in primary rat retinal cultures, whereas the nonspecific β-blocker timolol and another β1-AR-selective blocker metoprolol did not. These findings seem to demonstrate that the neuroprotective effect of betaxolol on retinal neurons is independent of β-AR interactions. The α2-agonist UK14,304 was also able to increase retinal cell survival in mixed retinal cultures after excitotoxic stress. This effect was both dose-dependent and receptor-mediated, because it was blocked by the α2-AR antagonist, yohimbine. Decrease in neuroprotection at higher doses of the α2-AR agonist may be associated with agonist-mediated receptor desensitization.45

An examination of the effect of betaxolol on NMDA-induced increases of [Ca$^{2+}$], in RGCs in isolated intact rabbit retina supports and extends previous results in isolated rat RGCs,46 showing that betaxolol inhibits glutamate-receptor stimulated increases of [Ca$^{2+}$], in RGCs in situ. The use of a different species and a different preparation strengthens the view that betaxolol is capable of limiting excitotoxicity arising from excessive or prolonged Ca$^{2+}$ influx. Glutamate-induced [Ca$^{2+}$] increases in isolated retinal neurons were also decreased by α2-AR agonists at doses comparable to those found to be neuroprotection in vitro. Therefore, some component of the neuroprotection afforded by betaxolol and α2-agonists in vitro and in vivo may be due to decreased Ca$^{2+}$ influx. A decrease in Ca$^{2+}$ influx would be expected to increase cell survival after excitotoxic stress by reducing activation of Ca$^{2+}$-dependent proteases and limiting free radical production and DNA damage.10,11,15

It has been demonstrated that certain β-AR blockers have additional properties unrelated to their actions at ARs that include actions at other receptors and ion channels. In the case of betaxolol but not other β-AR blockers such as propranolol, this includes block of voltage-dependent Ca channels in peripheral47 and retinal vasculature47,48 and inhibition of neuronal ion channels, Ca$^{2+}$ influx, and neuronal excitability.54,43,49,50 In our studies, metoprolol, a β1-AR blocker, failed to increase neuronal survival significantly at a concentration at which betaxolol had significant neuroprotective actions, and timolol, a nonselective β-AR blocker that has been shown not to have Ca channel-blocking action in cultured RGCs,43 was also ineffective at increasing retinal neuron survival in primary cultures. These data support the hypothesis that in the in vitro retinal cell models used, the neuroprotective actions of betaxolol can be primarily attributed to its direct suppressive actions on neuronal ion channels and Ca$^{2+}$ influx.

In contrast to the results obtained with betaxolol, our data suggest that the neuroprotective effects of UK14,304 on retinal neurons were mediated by a specific action at α2-ARs, in particular because the neuroprotection was blocked by the α2-AR antagonist yohimbine. These data are consistent with evidence that the α2-AR agonists brimonidine and clonidine are neuroprotective in animal models of ischemia, in pressure-induced retinal hypoxia, and after mechanical damage to RGC axons.59,51,52,51,52 The mechanism(s) for this in vivo neuroprotection also appears to involve α2-AR activation, because selective antagonists...
such as rauwolscine or yohimbine block the neuroprotection produced by agonist treatment.\textsuperscript{32,51}

Several lines of evidence have indicated that the mechanisms underlying α2-AR agonist-induced neuroprotection in the retina may include increased production of growth factors. For example, it has been suggested that photoreceptors are protected from light-induced damage by α2-AR agonists through the enhancement of basic fibroblast growth factor (bFGF) production.\textsuperscript{28} Upregulation of bFGF has been reported in several models of retinal ischemia,\textsuperscript{52–54} and it has been suggested that the neuroprotective actions of bFGF may include acting as a free radical scavenger and attenuating ascorbate-iron-induced formation of reactive oxygen species.\textsuperscript{52,53}

This pathway may be a mechanism for the neuroprotective properties of α2-AR agonists in the retina and may include nonneuronal targets such as retinal glia. In support of a nonneuronal action are data showing that in vivo administration of the α2-agonists clonidine and xylazine activates extracellular signal-regulated kinases p42/p44 primarily in Müller cells,\textsuperscript{55} an action that may indicate α2A-AR-mediated regulation of the release of neuroactive factors from Müller cells that could influence retinal neuronal survival.

Activation of neuronal α2-ARs may also act directly to decrease Ca\textsuperscript{2+} influx and excitatory transmitter release.\textsuperscript{56} Radioligand binding studies and cloning have demonstrated the presence of several α2-AR isoforms (α2A, α2C, and α2D) in the inner plexiform layer of the mammalian retina.\textsuperscript{56–58} In many types of neurons, α2-ARs are coupled to voltage-dependent N-type and P/Q type Ca channels through the Gi family of proteins to inhibit Ca\textsuperscript{2+} current, Ca\textsuperscript{2+} influx, and neurotransmitter release.\textsuperscript{59–61} RGCs and retinal neurons are known to express different Ca channel subtypes, including a toxin-resistant Ca\textsuperscript{2+} current component and N-type and L-type Ca\textsuperscript{2+} currents.\textsuperscript{62–63} Therefore, activation of α2-ARs may result in inhibition of Ca channels on retinal neurons.

Another laboratory has examined binding of the α2-AR agonist clonidine to voltage-dependent Ca and Na channels as well as the effects of clonidine on radiolabeled Ca\textsuperscript{2+} influx in intact isolated rat retina. Their studies have reported that, unlike betaxolol, clonidine did not directly interact with voltage-dependent L-type Ca channels or Na channels and did not produce a significant decrease in Ca\textsuperscript{2+} influx.\textsuperscript{52,64} Our data examining alterations of [Ca\textsuperscript{2+}], in isolated retinal neurons indicate that both UK14,304 and brimonidine can reduce the glutamate-induced increases of [Ca\textsuperscript{2+}], that may arise through receptor-mediated modulation of voltage-dependent Ca channels and/or release of Ca\textsuperscript{2+}-dependent stores. The inhibitory effect of UK14,304 on glutamate-induced increases of [Ca\textsuperscript{2+}], was reduced after pretreatment with the α2-AR agonist yohimbine, confirming that activation of α2-ARs on retinal neurons inhibits increases in glutamate-stimulated increases of [Ca\textsuperscript{2+}].

The findings of this study that both the β1-AR agonist betaxolol and the α2-AR agonists UK14,304 and brimonidine can increase survival of isolated retinal neurons in vitro confirm that these drugs can act as neuroprotectants through actions independent of vascular targets. The effective concentrations of drugs used in our studies of isolated cells and retina (1–100 μM) and others using isolated tissue preparations\textsuperscript{54–49} are in the clinically relevant range, estimated to be approximately 1 μM in plasma, with greater drug levels accumulating during prolonged administration.\textsuperscript{48,65} In vivo experiments in rats and monkeys using topical and systemic application of β-blockers indicate that levels of these drugs with repeated administration accumulate in the micromolar range in the retina and optic nerve head, with even greater levels present in the choroid, sclera, and iris ciliary body.\textsuperscript{56,67} Our results comparing different β-AR antagonists support and extend previous data by demonstrating that the neuroprotective properties of betaxolol in the retina are due, at least in part, to a direct effect on neurons, are independent of specific β-AR receptor interactions and probably arise from the actions of betaxolol on neuronal ion channels and [Ca\textsuperscript{2+}]i.\textsuperscript{34,43–49,50,52} In contrast to betaxolol, the survival-promoting actions of the α2-AR agonist UK14,304 occurred through the activation of α2-AR receptors. However, our data demonstrating that α2-AR agonists can modulate [Ca\textsuperscript{2+}]i, after exposure to glutamate suggest that in addition to other reported actions, such as increasing retinal levels of bFGF,\textsuperscript{26,52} they may also act directly on retinal neuron α2-AR receptors to limit increases in [Ca\textsuperscript{2+}]i.

References


34. Osborne NN, Caizeville C, Carvalho AL, Larsen AK, DeSantis L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 1997;751:113–123.

35. Wood JP, DeSantis L, Chao HM, Osborne NN. Topically applied betaxolol attenuates ischemia-induced effects to the rat retina and stimulates BNDF mRNA. Exp Eye Res. 2001;72:79–86.


